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Introduction
T-VEC is a herpes simplex virus type-1-derived oncoly-
tic immunotherapy designed to produce GM-CSF and
to selectively replicate in and lyse tumors to induce a
systemic anti-tumor immune response. A phase 3 study
of T-VEC in Stage IIIB-IV melanoma demonstrated a
significant improvement in ≥ 6 mo durable response
rate vs GM-CSF and a tolerable safety profile.
Methods
In this 2-part study (NCT01740297), phase 1b evaluated
the safety of T-VEC in combination with ipi as assessed
by the incidence of dose-limiting toxicities (DLTs) at
full doses of both agents. For 6 to 9 patients (pts) evalu-
able for DLT, approximately 18 pts were to be enrolled
in phase 1b. DLTs were defined as any grade (gr) ≥
3 immune-related adverse event (AE) or gr ≥ 4 AE of
any etiology occurring between the first dose of ipi and
6 wks after. The incidence of DLTs was required to be
≤ 1 of the first 6 evaluable pts or ≤ 2 of the first 9 eva-
luable pts (if 2 DLTs were seen in the first 6 pts). Key
entry criteria were previously untreated, unresectable
Stage IIIB-IV melanoma, ECOG 0-1, measurable disease,
and ≥ 1 injectable cutaneous, subcutaneous, or nodal
tumor. T-VEC was administered by intralesional injec-
tion at ≤ 4 mL of 106 plaque forming units (PFU)/mL
for the first dose, then 108 PFU/mL on day 1 of wk
4 and thereafter. Ipi 3 mg/kg q3w was administered as
4 infusions starting at wk 6. Pts received T-VEC until
development of DLT, all injectable tumors have disap-
peared, disease progression per the Immune Related
Response Criteria, or treatment intolerance. Phase 2 will
evaluate the safety and efficacy of ipi vs T-VEC+ipi in a
randomized fashion.
Results
To date, 19 pts have enrolled (13 pts received ≥ 1 dose
of T-VEC); 9 pts are evaluable for DLT. All DLT evalu-
able pts received at least 4 doses of T-VEC and 2 doses
of ipi by the time of DLT cutoff (6 wks post first ipi
dose). No DLTs were observed in evaluable pts. Serious
AEs were reported in 1 of 19 pts to date (gr 3 nausea
and abdominal distention in week 11 of treatment). Two
partial responses were reported by wk 12 in the 9 DLT
evaluable pts. Data will be updated at the meeting.
Conclusions
Advancement into the randomized phase 2 is planned
pending Data Review Team recommendations.
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